Suppr超能文献

DTX3L和ARTD9抑制IRF1表达,并与ARTD8协同介导转移性前列腺癌细胞的存活和增殖。

DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.

作者信息

Bachmann Samia B, Frommel Sandra C, Camicia Rosalba, Winkler Hans C, Santoro Raffaella, Hassa Paul O

机构信息

Institute of Veterinary Biochemistry and Molecular Biology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.

出版信息

Mol Cancer. 2014 May 27;13:125. doi: 10.1186/1476-4598-13-125.

Abstract

BACKGROUND

Prostate cancer (PCa) is one of the leading causes of cancer-related mortality and morbidity in the aging male population and represents the most frequently diagnosed malignancy in men around the world. The Deltex (DTX)-3-like E3 ubiquitin ligase (DTX3L), also known as B-lymphoma and BAL-associated protein (BBAP), was originally identified as a binding partner of the diphtheria-toxin-like macrodomain containing ADP-ribosyltransferase-9 (ARTD9), also known as BAL1 and PARP9. We have previously demonstrated that ARTD9 acts as a novel oncogenic survival factor in high-risk, chemo-resistant, diffuse large B cell lymphoma (DLBCL). The mono-ADP-ribosyltransferase ARTD8, also known as PARP14 functions as a STAT6-specific co-regulator of IL4-mediated proliferation and survival in B cells.

METHODS

Co-expression of DTX3L, ARTD8, ARTD9 and STAT1 was analyzed in the metastatic PCa (mPCa) cell lines PC3, DU145, LNCaP and in the normal prostate luminal epithelial cell lines HPE and RWPE1. Effects on cell proliferation, survival and cell migration were determined in PC3, DU145 and/or LNCaP cells depleted of DTX3L, ARTD8, ARTD9, STAT1 and/or IRF1 compared to their proficient control cells, respectively. In further experiments, real-time RT-PCR, Western blot, immunofluorescence and co-immunoprecipitations were conducted to evaluate the physical and functional interactions between DTX3L, ARTD8 and ARTD9.

RESULTS

Here we could identify DTX3L, ARTD9 and ARTD8 as novel oncogenic survival factors in mPCa cells. Our studies revealed that DTX3L forms a complex with ARTD8 and mediates together with ARTD8 and ARTD9 proliferation, chemo-resistance and survival of mPCa cells. In addition, DTX3L, ARTD8 and ARTD9 form complexes with each other. Our study provides first evidence that the enzymatic activity of ARTD8 is required for survival of mPCa cells. DTX3L and ARTD9 act together as repressors of the tumor suppressor IRF1 in mPCa cells. Furthermore, the present study shows that DTX3L together with STAT1 and STAT3 is implicated in cell migration of mPCa cells.

CONCLUSIONS

Our data strongly indicate that a crosstalk between STAT1, DTX3L and ARTD-like mono-ADP-ribosyltransferases mediates proliferation and survival of mPCa cells. The present study further suggests that the combined targeted inhibition of STAT1, ARTD8, ARTD9 and/or DTX3L could increase the efficacy of chemotherapy or radiation treatment in prostate and other high-risk tumor types with an increased STAT1 signaling.

摘要

背景

前列腺癌(PCa)是老年男性人群中癌症相关死亡率和发病率的主要原因之一,也是全球男性中最常被诊断出的恶性肿瘤。类Deltex(DTX)-3 E3泛素连接酶(DTX3L),也被称为B淋巴细胞和BAL相关蛋白(BBAP),最初被鉴定为含有ADP-核糖基转移酶-9(ARTD9,也称为BAL1和PARP9)的白喉毒素样大结构域的结合伴侣。我们之前已经证明,ARTD9在高危、化疗耐药的弥漫性大B细胞淋巴瘤(DLBCL)中作为一种新的致癌生存因子发挥作用。单ADP-核糖基转移酶ARTD8,也称为PARP14,在B细胞中作为IL4介导的增殖和生存的STAT6特异性共调节因子发挥作用。

方法

在转移性前列腺癌细胞系PC3、DU145、LNCaP以及正常前列腺腔上皮细胞系HPE和RWPE1中分析DTX3L、ARTD8、ARTD9和STAT1的共表达情况。分别在DTX3L、ARTD8、ARTD9、STAT1和/或IRF1缺失的PC3、DU145和/或LNCaP细胞与其相应的正常对照细胞中,测定对细胞增殖、生存和细胞迁移的影响。在进一步的实验中,进行实时RT-PCR、蛋白质印迹、免疫荧光和免疫共沉淀,以评估DTX3L、ARTD8和ARTD9之间的物理和功能相互作用。

结果

在这里,我们可以确定DTX3L、ARTD9和ARTD8是转移性前列腺癌细胞中的新型致癌生存因子。我们的研究表明,DTX3L与ARTD8形成复合物,并与ARTD8和ARTD9一起介导转移性前列腺癌细胞的增殖、化疗耐药性和生存。此外,DTX3L、ARTD8和ARTD9相互形成复合物。我们的研究提供了首个证据,即ARTD8的酶活性是转移性前列腺癌细胞生存所必需的。DTX3L和ARTD9在转移性前列腺癌细胞中共同作为肿瘤抑制因子IRF1的抑制剂发挥作用。此外,本研究表明,DTX3L与STAT1和STAT3一起参与转移性前列腺癌细胞的迁移。

结论

我们的数据强烈表明,STAT1、DTX3L和类ARTD单ADP-核糖基转移酶之间的相互作用介导了转移性前列腺癌细胞的增殖和生存。本研究进一步表明,联合靶向抑制STAT1、ARTD8、ARTD9和/或DTX3L可以提高前列腺癌和其他STAT1信号增强的高危肿瘤类型的化疗或放疗疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bb2/4070648/4b59b86b2cd8/1476-4598-13-125-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验